Journal
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume 49, Issue 3, Pages 317-326Publisher
HUMANA PRESS INC
DOI: 10.1007/s12016-015-8469-8
Keywords
Hydroxychloroquine; Chloroquine; Antimalarials; Systemic lupus erythematosus; Retinopathy; Drug toxicity
Categories
Ask authors/readers for more resources
Hydroxychloroquine (HCQ) and chloroquine have been used for more than 50 years to treat systemic lupus erythematosus (SLE) and other rheumatic diseases. In general, these drugs are well tolerated and rarely need to be discontinued because of an adverse systemic reaction. However, both medications can be irreversibly toxic to the retina. A new study indicates that toxicity is not as rare as once believed, but depends critically on daily dosage and duration of use, as well as other risk factors. With attention to dosage and other factors, and with proper screening for early signs of toxicity, HCQ can be prescribed with relative safety even over long periods of time.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available